WO2000022124A3 - Methods and compositions to induce antitumor response - Google Patents
Methods and compositions to induce antitumor response Download PDFInfo
- Publication number
- WO2000022124A3 WO2000022124A3 PCT/US1999/021454 US9921454W WO0022124A3 WO 2000022124 A3 WO2000022124 A3 WO 2000022124A3 US 9921454 W US9921454 W US 9921454W WO 0022124 A3 WO0022124 A3 WO 0022124A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- compositions
- present
- dendritic
- induce
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000006023 anti-tumor response Effects 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 5
- 238000001727 in vivo Methods 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 239000002975 chemoattractant Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64977/99A AU6497799A (en) | 1998-10-15 | 1999-10-14 | Methods and compositions to induce antitumor response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17320398A | 1998-10-15 | 1998-10-15 | |
US09/173,203 | 1998-10-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000022124A2 WO2000022124A2 (en) | 2000-04-20 |
WO2000022124A3 true WO2000022124A3 (en) | 2000-07-06 |
Family
ID=22630966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/021454 WO2000022124A2 (en) | 1998-10-15 | 1999-10-14 | Methods and compositions to induce antitumor response |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6497799A (en) |
WO (1) | WO2000022124A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7229621B2 (en) | 1998-10-20 | 2007-06-12 | Torrey Pines Institute For Molecular Studies | Method to enhance the immunogenicity of an antigen |
US7361329B2 (en) | 2000-04-21 | 2008-04-22 | Chemocentryx, Inc. | Compositions for inducing an immune response |
AU2002225927A1 (en) * | 2000-11-17 | 2002-05-27 | Immunex Corporation | Chemoattractant recruitment of dendritic cells for enhancement of immunization |
US7109029B2 (en) | 2001-02-23 | 2006-09-19 | Cell Genesys, Inc. | Vector constructs |
MX2015014438A (en) | 2013-04-18 | 2016-05-18 | Armo Biosciences Inc | Methods of using interleukin-10 for treating diseases and disorders. |
US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011984A2 (en) * | 1993-10-25 | 1995-05-04 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5677178A (en) * | 1993-02-16 | 1997-10-14 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
WO1998015285A1 (en) * | 1996-10-10 | 1998-04-16 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for inducing a protective immune response to cancers |
WO1998021330A1 (en) * | 1996-11-15 | 1998-05-22 | Indiana University Foundation | Exodus chemokine materials and methods |
WO1998021228A1 (en) * | 1996-11-15 | 1998-05-22 | Canji, Inc. | Tissue specific expression of retinoblastoma protein |
WO1998039464A2 (en) * | 1997-03-03 | 1998-09-11 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
WO1999047169A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Methods to provoke anti-cancer immune responses |
-
1999
- 1999-10-14 AU AU64977/99A patent/AU6497799A/en not_active Abandoned
- 1999-10-14 WO PCT/US1999/021454 patent/WO2000022124A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677178A (en) * | 1993-02-16 | 1997-10-14 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
WO1995011984A2 (en) * | 1993-10-25 | 1995-05-04 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
WO1998015285A1 (en) * | 1996-10-10 | 1998-04-16 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for inducing a protective immune response to cancers |
WO1998021330A1 (en) * | 1996-11-15 | 1998-05-22 | Indiana University Foundation | Exodus chemokine materials and methods |
WO1998021228A1 (en) * | 1996-11-15 | 1998-05-22 | Canji, Inc. | Tissue specific expression of retinoblastoma protein |
WO1998039464A2 (en) * | 1997-03-03 | 1998-09-11 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
WO1999047169A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Methods to provoke anti-cancer immune responses |
Non-Patent Citations (5)
Title |
---|
DIEU M-C ET AL.: "Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 2, 20 July 1998 (1998-07-20), pages 373 - 386, XP002133972 * |
HE X-S ET AL.: "Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein", GENE, vol. 175, no. 1/2, 10 October 1996 (1996-10-10), pages 121 - 125, XP002041764 * |
ISHIDA T ET AL.: "Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08-01), pages 244 - 251, XP000891464 * |
SHERMAN L A ET AL.: "Strategies for tumor elimination by cytotoxic T lymphocytes", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 18, no. 1-2, 1998, pages 47 - 54, XP000877347 * |
SONG W ET AL.: "Dendritic cells genetically modified with and adenovirus vector encoding the cDNA for a model antigen induce protective", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1247 - 1256, XP002133971 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Also Published As
Publication number | Publication date |
---|---|
AU6497799A (en) | 2000-05-01 |
WO2000022124A2 (en) | 2000-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2265980T5 (en) | METHODS RELATED TO INTERFERON INDUITED BY IMMUNE STIMULATING NUCLEIC ACIDS. | |
WO1998055495A3 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
CA2182303A1 (en) | Method of preparing a viral vector by homologous intermolecular recombination | |
ZA988124B (en) | Mage-3 peptides presented by HLA class II molecules | |
PL337019A1 (en) | Peptide-coated implants and method of obtaining them | |
WO1999061601A3 (en) | Aav5 vector and uses thereof | |
EP0584266A4 (en) | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof. | |
AU4078599A (en) | Expression vectors for stimulating an immune response and methods of using the same | |
WO1995024485A3 (en) | Coordinate in vivo gene expression | |
CZ63995A3 (en) | Virus vectors and their use in gene therapy | |
WO2002049669A3 (en) | Electrically responsive promoter system | |
HK1031097A1 (en) | Processes for preparing nucleic acid constructs | |
WO1999062923A3 (en) | Immunostimulatory oligonucleotides with modified bases and methods of use thereof | |
WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
CA2323086A1 (en) | Regulation of endogenous gene expression in cells using zinc finger proteins | |
WO1999029341A3 (en) | Methods for enhancement of protective immume responses employing leishmania polypeptides | |
EP0633943A4 (en) | Gene therapy using targeted viral vectors. | |
AU2284697A (en) | Fusogenic liposomes | |
WO1998034952A3 (en) | Il-2 gene expression and delivery systems and uses | |
IL135687A0 (en) | A novel human checkpoint kinase, hcds1, compositions and methods | |
WO2000022124A3 (en) | Methods and compositions to induce antitumor response | |
WO1999024077A3 (en) | Compositions and methods for targeted delivery of biologically-active factors | |
WO2004035799A3 (en) | Viral vectors and the use of the same for gene therapy | |
SI1212428T1 (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression | |
WO1998058055A3 (en) | Antisense nucleic acids targeting hbv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 64977 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |